SEC Form 4Coverage since May 26, 2026
$NTRA insider trading
Over the last 12 months, Natera insiders reported no purchases and 55 sales totaling $83.3M across SEC Form 4 filings. 87% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $83.3M 55 events
- Events · 12m
- 55 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 87% pre-arranged plans
Side
Price · $NTRA · 12Mvia TradingView
Top insiders · 12m
Chapman Steven LeonardCEO AND PRESIDENT16× · $11.4M
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS8× · $3.3M
Sheena Jonathan—7× · $5.3M
BOTHA ROELOF—6× · $17.2M
Rabinowitz MatthewEXECUTIVE CHAIRMAN5× · $23.0M
All insider trades
55 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN · O·D | ▼ Sale | 2,000 | $320.9 | $642K | -50% | plan · indirect |
| Aug 7, 2026 | Sheena JonathanD | ▼ Sale | 9,150 | $315.66 | $2.9M | -3.7% | plan · 10 tranches |
| Aug 4, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER · O | ▼ Sale | 795 | $271.74 | $216K | -1.5% | plan · 2 tranches |
| Aug 3, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 3,076 | $266.39 | $819K | -3% | plan · 7 tranches |
| Aug 3, 2026 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER · O | ▼ Sale | 295 | $267.99 | $79K | -0.2% | plan |
| Aug 3, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 3,410 | $265.58 | $906K | -2.6% | plan · 7 tranches |
| Aug 3, 2026 | RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER · O | ▼ Sale | 334 | $267.99 | $90K | -0.2% | plan |
| Aug 3, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN · O·D | ▼ Sale | 731 | $267.99 | $196K | — | plan |
| Aug 3, 2026 | Sheena JonathanD | ▼ Sale | 109 | $267.99 | $29K | — | plan |
| Jul 29, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER · O | ▼ Sale | 5,064 | $253.28 | $1.3M | -8.8% | plan · 5 tranches |
| Jul 28, 2026 | Sheena JonathanD | ▼ Sale | 479 | $257.93 | $124K | -0.2% | plan · 2 tranches |
| Jul 28, 2026 | RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER · O | ▼ Sale | 1,887 | $257.08 | $485K | -1.1% | plan · 2 tranches |
| Jul 28, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 2,214 | $257 | $569K | -1.6% | plan · 2 tranches |
| Jul 28, 2026 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER · O | ▼ Sale | 1,713 | $257 | $440K | -0.9% | plan · 2 tranches |
| Jul 28, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 5,770 | $256.51 | $1.5M | -5.3% | plan · 2 tranches |
| Jul 27, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN · O·D | ▼ Sale | 1,718 | $260.49 | $448K | -0.1% | plan |
| Jul 15, 2026 | Sheena JonathanD | ▼ Sale | 1,500 | $273.88 | $411K | -7.7% | plan · 8 tranches · indirect |
| Jul 15, 2026 | Chapman Rowan ED | ▼ Sale | 135 | $274.82 | $37K | -2.8% | plan |
| Jul 13, 2026 | Sheena JonathanD | ▼ Sale | 3,150 | $265.68 | $837K | -1.3% | plan · 6 tranches |
| Jul 6, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN · O·D | ▼ Sale | 1,000 | $280 | $280K | -20% | plan · indirect |
| Jul 1, 2026 | RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER · O | ▼ Sale | 16,800 | $272.29 | $4.6M | -8.9% | plan · 12 tranches |
| Jul 1, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 3,000 | $272.9 | $819K | -2.2% | plan · 3 tranches |
| Jun 24, 2026 | RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER · O | ▼ Sale | 33,600 | $251.65 | $8.5M | -15.1% | plan · 4 tranches |
| Jun 24, 2026 | ROSENMAN HERMD | ▼ Sale | 16,530 | $250 | $4.1M | -79.5% | plan |
| Jun 17, 2026 | Sheena JonathanD | ▼ Sale | 1,500 | $219.87 | $330K | -7.4% | plan · 9 tranches · indirect |
| Jun 16, 2026 | Chapman Rowan ED | ▼ Sale | 2,964 | $216.78 | $643K | -48.7% | plan |
| Jun 15, 2026 | Sheena JonathanD | ▼ Sale | 3,150 | $211.14 | $665K | -1.2% | plan · 4 tranches |
| Jun 15, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN · O·D | ▼ Sale | 100,000 | $214.47 | $21.4M | -4.2% | plan · 21 tranches |
| Jun 5, 2026 | Marcus Gail BoxerD | ▼ Sale | 11,000 | $217.21 | $2.4M | -64% | 4 tranches |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 3,409 | $226.97 | $774K | -3% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 6,751 | $226.15 | $1.5M | -5.7% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 1,630 | $224.99 | $367K | -1.4% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 1,443 | $223.91 | $323K | -1.2% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 6,500 | $223.34 | $1.5M | -5.1% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 2,006 | $222.25 | $446K | -1.5% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 2,400 | $220.19 | $528K | -1.8% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 2,758 | $219.08 | $604K | -2% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 1,742 | $218.28 | $380K | -1.3% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 2,351 | $217.04 | $510K | -1.7% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 5,499 | $216.13 | $1.2M | -3.8% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 1,300 | $214.83 | $279K | -0.9% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 2,503 | $213.44 | $534K | -1.7% | plan |
| Jun 4, 2026 | Chapman Steven LeonardCEO AND PRESIDENT · O·D | ▼ Sale | 832 | $212.42 | $177K | -0.6% | plan |
| Jun 1, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 572 | $220.67 | $126K | -0.4% | plan |
| Jun 1, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 213 | $219.34 | $47K | -0.2% | plan |
| Jun 1, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 413 | $218.84 | $90K | -0.3% | plan |
| Jun 1, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 1,802 | $217.52 | $392K | -1.3% | plan |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 2,450 | $223.83 | $548K | -0.2% | indirect |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 2,850 | $222.79 | $635K | -0.3% | indirect |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 14,885 | $221.58 | $3.3M | -1.4% | indirect |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 21,304 | $220.94 | $4.7M | -1.9% | indirect |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 10,100 | $219.78 | $2.2M | -0.9% | indirect |
| Jun 1, 2026 | BOTHA ROELOFD | ▼ Sale | 26,411 | $218.69 | $5.8M | -2.3% | indirect |
| May 26, 2026 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER · O | ▼ Sale | 1,438 | $202.84 | $292K | -0.8% | plan |
| May 26, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS · O | ▼ Sale | 1,652 | $202.84 | $335K | -1.2% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NTRA feed.